MYND Life Sciences Inc. (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of drug therapies and ...

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

The anesthetic ketamine is being hailed as a breakthrough therapy for people with post-traumatic stress disorder (PTSD), ...

Federal authorities say two shipments containing a deadly, addictive and illegal substance was seized at the port of Cincinnati.

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

One of DOGE's engineers dispatched to take over the Education Department used to have a very different title: ketamine dealer ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on delivering therapeutics through effective oral delivery, announced today that it has received revised regulatory guidance for LPCN ...

Neumora Therapeutics Inc. concealed critical issues with its flagship clinical depression drug’s Phase 2 trial, contributing ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Green, who was coming off a year-long suspension in 2010 after testing positive for marijuana, tested positive for marijuana ...

Green, who was coming off a year-long suspension in 2010 after testing positive for marijuana, tested positive for marijuana ...